With three products out, Aratana chases its fourth: a canine cancer drug
With its third FDA-approved drug on the market, Aratana Therapeutics is hunting its next product, a canine cancer immunotherapy treatment.
The treatment, called AT-014, would be used to treat bone cancer, or osteosarcoma, in dogs. After a tumor is removed, a vaccine is used to prime the dog’s immune system to target any remaining cancer.
Aratana (Nasdaq: PETX) expects to obtain conditional licensure for the treatment from the U.S . Department of Agriculture before the end of 2017, which would…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
More News: Bone Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Immunotherapy | Osteosarcoma | Pharmaceuticals | Vaccines